Tudor Investment Corp
NEOS

Tudor Investment Corp’s Neos Therapeutics, Inc NEOS Stock Holding History

Tudor Investment Corp’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20,000
Closed -$146K – 1316
2017
Q2 		$146K Buy
+20,000
New +$151K ﹤0.01% 929

Other funds holding NEOS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tudor Investment Corp's NEOS Position: Q3 2017 in Review

Tudor Investment Corp sold out of Neos Therapeutics, Inc (NEOS) in Q3 2017, closing a stake of 20,000 shares — an estimated $146K sold.

Tudor Investment Corp first reported a position in NEOS in Q2 2017 and held it in 1 quarter. The position peaked at $146K in Q2 2017. 63 funds tracked by Wall St. Rank hold NEOS as of Q3 2017.

  • Tudor Investment Corp reported no remaining Neos Therapeutics, Inc position as of Q3 2017 after selling out during the quarter.
  • Tudor Investment Corp sold 20,000 Neos Therapeutics, Inc shares in Q3 2017, an estimated $146K.
  • Tudor Investment Corp first reported a position in Neos Therapeutics, Inc in Q2 2017 and held it in 1 quarter.
  • Tudor Investment Corp's Neos Therapeutics, Inc position peaked at $146K in Q2 2017.
  • 63 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q3 2017.

Based on Tudor Investment Corp's 13F filing for Q3 2017, filed 14 Nov 2017.